NCT03450122View on ClinicalTrials.gov

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

December 6, 2022

Study Completion Date

December 6, 2022

Conditions
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Myxoid LiposarcomaRecurrent Synovial Sarcoma
Interventions
BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Autologous NY-ESO-1-specific CD8-positive T Lymphocytes

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Dendritic Cell-targeting Lentiviral Vector ID-LV305

Given ID

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03450122 - Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma | Biotech Hunter | Biotech Hunter